and kynurenine (KYn) production represents an attractive target for reducing tumour progression and improving anti-tumour immunity in multiple cancers. However, immunomodulatory properties of other KP metabolites such as 3-hydroxy kynurenine (3-HK) and kynurenic acid (KYNA) are poorly understood. the association of the kynurenine metabolic pathway with t-cell status in the tumour microenvironment were characterized, using gene expression data of 368 cutaneous skin melanoma (SKCM) patients from the TCGA cohort. Based on the identified correlations, we characterized the production of KYN, 3-HK, and KYNA in vitro using melanoma-derived cell lines and primary CD4+ CD25− T-cells. Activation of the CD4+ t-cells produced ifnγ, which yielded increased levels of KYn and KYNA. Concurrently, kynurenine 3-monooxygenase (KMO) expression and proliferation of CD4+ t-cells were reduced, whereas exhaustion markers such as PD-L1, AHR, FOXP3, and CTLA4 were increased. Additionally, an analysis of the correlation network reconstructed using tcGA-SKcM emphasized KMo and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity. Our results suggest that, in addition to IDO1, there is an alternative immune regulatory mechanism associated with the lower KMo expression and the higher KYNA production, which contributes to dysfunctional effector CD4+ t-cell response.
Inhibition of CD4+CD25− t-cell proliferation by melanoma cell lines (McLs) associated with
Kp enzymatic alteration. In order to characterize how melanoma tumours influence the CD4+ CD25− T-cells, healthy donors' pre-activated primary CD4+CD25− T-cells were co-cultured with human cutaneous melanoma cell lines, including DFB, A375, and SK-MEL-28 (V600E) and BE and SK-MEL-2 (V600 wt), for five days (Fig. 2a ). As expected, the proliferation and IFNγ production of CD4+ T-cells was significantly reduced when co-cultured with MCLs ( Fig. 2b,d) or with supernatant harvested from MCLs ( Fig. 2e ). Furthermore, CD4+ T-cells had a higher expression of CTLA4 and FOXP3 in the presence of MCLs (Fig. 2f,g) . Collectively, these observations may suggest the development of an exhausted CD4+ T-cell phenotype. To determine whether changes in KP metabolite may involve CD4+ T-cells exhaustion, KP metabolites concentration was measured by HILIC-MS/MS in supernatant derived from each cell type alone or co-cultured after 48 hours. This analysis showed a profound depletion of TRP, 3-HK production, and higher production KYN, KYNA in co-cultures compared with the medium from MCLs and CD4+ T-cells alone (Fig. 2k ,l,k, Supplementary Fig. 1b-g) .
Therefore, we then investigated whether KYN and KYNA production promotes an exhausted CD4+ T-cell phenotype upon exposure to MCLs. To this end, mRNA and protein expression of IDO1 and mRNA expression of IDO2, TDO2 which mediate the production of KYN were compared in both CD4+ T-cells and MCLs before 
IDO1 blockade repairs CD4 + t-cells proliferation in culture with McLs. To further investigate
whether IDO1 blockade and KYN depletion can recover CD4+ T-cell proliferation, MCLs (BE, DFB, A375, and SK-MEL-28) were cultured for 48 hours with CD4+ T-cells in the presence or absence of IDO1 inhibitor INCB024360 (Epacadostat). CD4+ T-cells proliferation was recovered in culture with MCLs ( Fig. 3a ) while the IDO1 inhibition led to lower KYN production in co-culture set-up. IDO1 inhibition also led to lower CTLA4 protein expression from educated CD4+ T-cells ( Fig. 3b ,c), although the mRNA levels of cytokines did not differ significantly upon IDO1 blockade ( Fig. 3d-f ). Interestingly, CD4+ T-cells were more proliferative in a BRAF wt cell line compared with V600E cell lines in the presence of the IDO1 blockade ( Supplementary Fig. 3b ) which may suggest the possible relation between mutation status and KP metabolites in district CD4+ T-cell behavior in co-culture set-up. CD4+ t-cell behavior in co-culture set-up is linked to KYnA production. In order to investigate the role of the KP metabolites in district CD4+ T-cell behavior in co-culture set-up, CD4+ T-cell proliferation and KP metabolites in each culture were evaluated separately. In the closer look, we noticed CD4+ T-cells were less proliferative in the presence of BRAF wt MCLs compared with V600E MCLs (Fig. 4a ). Despite Tryptophan depletion, no significant differences were detected in KYN production among different MCLs ( Supplementary  Fig. 1b, Fig. 4b ). Therefore, to convey the anti-proliferative role of TRP depletion on CD4+ T-cell, a rescue experiment was conducted by adding TRP on co-culture set-up. Subsequently, CD4+ T-cell proliferation was measured, which revealed that additional TRP did not restore CD4+ T-cell proliferation ( Supplementary Fig. 3a ). Thus, it is possible that TRP depletion itself may not have any anti-proliferative effect on CD4+ T-cells. On the other hand, KYNA production was higher in V600 wt MCLs (BE) co-cultured with CD4+ T-cells compared with V600E cell lines (A375, SK-MEL-28, and DFB). Interestingly, the PD-L1 and AHR mRNA expression were higher in BRAF wt MCLs cultured with CD4+ T-cell compared with V600E MCLs (Fig. 4d,f ). However, AHR mRNA expression was also higher in CD4+ T-cells upon co-culture with V600E MCLs (Fig. 4e ). This observation suggests that functional implications of elevated KYNA and CD4+ T-cell exhaustion may be regulated by PD-L1 and AHR expression. We, therefore, further evaluated the effect of KYNA production on CD4+ T-cell proliferation. 0.005, ***P ≤ 0.0005 by One-Way ANOVA (non-parametric) and independent samples t-test (two-sided) and the Tukey multiple comparison procedure was used to determine significance; and adjusted P values for the differences in group means can be seen in Table S6 , n > three biological replicates cultured with four different melanoma cell lines.
www.nature.com/scientificreports www.nature.com/scientificreports/ To investigate the potential role of KYNA in CD4+ T-cell exhaustion, CD4+ T-cell were treated with different concentrations of KYNA (0,005-50 µM). The proliferation of CD4+ T-cell and IFNγ production measured on day five and reveals that the presence of KYNA can revoke the CD4+ T-cell proliferation and IFNγ production ( Fig. 4g -j). Figure 4g show representative images of gating strategy (left panel), IFNγ production (right upper panel) and CD4+ T-cell proliferation (right lower panel) in different concentrations of KYNA. Cell toxic concentration of KYNA was defined using viability assay by flow cytometry and concentrations of KYNA lower than 0.05 µM did not show any toxicity ( Fig. 4h ) and concentration 0.05 μM effectively inhibited CD4+ T-cell proliferation and IFNγ production ( Fig. 4i,j) .
Moreover, to verify the association of BRAF wt status on CD4+ T-cell exhaustion, V600E cell lines (SK-MEL-28 and DFB) were transiently transfected with expression vector encoding BRAF wild-type and co-cultured with CD4+ T-cell for five days (Fig. 4k ). The proliferation of CD4+ T-cell and IFNγ production was measured on day five which supports that BRAF wt phenotype has a profound effect on CD4+ T-cell exhaustion when compared to BRAF V600E ( Fig. 4k-m ).
ifnγ triggers KYN and KYNA production but not 3-HK of melanoma tumours. Due to the close link between KP activation and inflammatory stimuli, a Type 1 T helper (Th1) cells cytokine profile including
IFNγ, TNFα, IL-2 and Type 2 T helper (Th2) cytokine profile including IL-4, IL-2 and IL-10 were performed on culture supernatants and measured using a multiplex Luminex assay ( Fig. 5a ). IFNγ and TNFα were the central cytokines which were continuously secreted upon CD4+CD25− T-cell activation in our set-up. IL-2 production, which is a critical cytokine for T-cells survival and maintenance, was not changed in the co-culture set up (Fig. 5a ). In order to investigate the role of IFNγ and TNFα on KP activation, MCLs were treated with recombinant human IFNγ (50 ng/ml) and TNFα (10 ng/ml) for 48 hours. We did not observe any changes after TNFα treatment in IDO1 expression or KYN production. Furthermore, IFNγ treatment was able to induce the KYN, KYNA, and AA production while the 3-HK production stayed very low ( Supplementary Fig. 3b-e ). Moreover, CD4+ T-cells were less proliferative in culture with conditioned medium (CM) derived from IFNγ treated MCLs compared with CM derived from MCLS+CD4+ T-cell co-culture (Fig. 5c ). The elevated KYNA may explain this Table S6 , n > three biological replicates cultured with four different melanoma cell lines.
Profiling the correlation networks for CD4+ T-cell and KP-related genes in BRAF V600E compared with BRAf wt SKcM.
Our results suggest the possible relation between the mutation status of the MCLs and KP metabolites in district CD4+ T-cell behaviour in co-culture set-up. We, therefore, evaluated whether KP retains dissimilar anti-tumoural CD4+ T-cell immune response in BRAF V600E compared with BRAF wt SKCM in a broader cohort or not. We reconstructed a network by thresholding Spearman correlation among CD4+ T-cells and KP-related genes for each group (BRAF V600E & BRAF wt). The signature genes associated with the CD4+ T-cells and KP were extracted from PubMed (Table S5) , using patient data available in the TCGA database (SKCM, 2016). We then used these Spearman correlation values (absolute value of Spearman correlation ≥0.5) between CD4+ T-cell representative genes and metabolites of interest to reconstruct networks ( Fig. 6a,b) . To visualize the difference between these two networks, we then merged both networks using DyNet. Differences between the two networks based on variation in node betweenness were highlighted in the merged network (Fig. 6c ). Comparing the structure of these networks revealed interesting structural dissimilarities between BRAF V600E and BRAF wt networks. First, we characterized the network's topological parameters [clustering coefficient, network centralization, network density, network diameter, network heterogeneity, and network radius (Fig. 6d ).
The number of interactions in the BRAF V600E network was less than BRAF wt, while both centrality and heterogeneity of the network were increasing (Fig. 6d) . Nodes in the BRAF wt network tended to have a higher degree than those in the BRAF V600E network. The total number of edges of the BRAF wt network (n = 616) was significantly higher than the BRAF V600E network (n = 444). The median degree value of 20 in the BRAF wt network decreased to 14.5 in the BRAF V600E network. The magnitude of the average clustering coefficient went down from 0.73 for the BRAF wt network to 0.62 in the BRAF V600E network, indicating greater clustering tendency of the BRAF wt network. All of these changes indicated distinct properties of the BRAF V600E and BRAF wt networks). KYNU, IDO1/2, and KMO had the highest degree and were among the top-ranked nodes in terms of other topological properties in the BRAF wt network (Table S6 ). The topological profile of KYNU and KMO in BRAFV600E-network changed utterly. They, lost their central role in the network while IDO1 and IDO2 almost kept the same topological profiles (Fig. 6e,f) . Interestingly, the EdgeBetweenness of CD86-KYNU increased from almost the bottom-ranked EdgeBetweenness (411) in BRAF wt to top-ranked (6) in BRAF V600E (Table S6) which suggests that perturbing (removing) these two nodes can have a considerable effect on the BRAF V600E network. These remarks support our previous observation in co-culture set-up and suggest that KMO and KYNU may play a role in district CD4+ T-cell behaviour in tumour immunity.
Collectively, KP and CD4+ T-cell interactions in the BRAF wt and V600E networks suggest that kynurenine metabolism may have an essential role in the dysregulation of the anti-tumoural CD4+ T-cell immune response.
Discussion
In the present study, we established an in vitro co-culture model consisting of CD4+CD25-T-cells obtained from healthy volunteers in culture with four different MCLs (BRAF wt and BRAF V600E) to investigate the implication of kynurenine pathway alteration on CD4+ T-cell function. We found that the enzymatic activity of IDO1 is significantly up-regulated in MCLs when exposed to IFNγ producing CD4+ T-cells. Supporting our results, the analysis of the SKCM-TCGA database revealed a robust correlation between KP enzymes and inhibitory checkpoints ( Fig. 1b, Supplementary Fig. 5b ). Furthermore, higher KYN and KYNA production resulted in an anergic phenotype in CD4+ T-cells, with defects in proliferation.
Additionally, by using correlation networks between kynurenine pathway metabolites and CD4+ T-cell parameters, we identified KMO and KYNU as central nodes in network diagrams built around data from BRAF V600E and BRAF wt in SKCM -TCGA data. These findings not only support the immunomodulatory potential of the kynurenine pathway in the tumour microenvironment but also display KMO and KYNU alteration in the kynurenine pathway that regulates the immune function of CD4+ T-cells. Besides, the full spectrum of TRP metabolites towards KP, upon exposure of CD4+ T-cells to MCLs, showed that Th1-type cytokines IFNγ led to a higher production of KYN and KYNA compared with 3-HK.
On the other hand, KYNA production was notably higher in BRAF wt MCLs co-cultured with CD4+ T-cells compared with BRAF V600E cell lines, although no significant differences were detected in KYN production www.nature.com/scientificreports www.nature.com/scientificreports/ among different MCLs. Furthermore, treating MCLs with IFNγ alone led to a higher production of KYNA in BRAF wt MCL compared with BRAF V600E MCLs. In addition, CD4+ T-cells were less proliferative in culture with VE600wt MCLs compared with VE600E MCLs, which may reflect the critical role of elevated KYNA on the induction of CD4+ T-cell exhaustion in co-culture set-up. Additionally, the lower mRNA KMO expression in CD4+ T-cells and elevated level of KYNA upon co-culture may propose KMO as an enzyme that is crucial for determining the levels of KYNA, which has also been reported elsewhere 34 .
Our data also support the idea that Epacadostat (INCB024360), a potent inhibitor of IDO1 with direct reactivation of CD4+ T-cells in vitro 35 , mediates the proliferation of CD4+ T-cells and abrogates CTLA4 expression on CD4+ T-cells and PD-L1 expression in MCLs ( Supplementary Fig. 2f ). Recent studies with a combination of INCB024360 and the PD-1 blockade (pembrolizumab) in patients with advanced melanoma did not show any significant improvement compared with the single PD-1 blockade, which supports the clinical relevance of our studies and indicates that IDO1 inhibition alone will not enhance the effect of immune checkpoint blockade 7, 36 .
Altogether, our data suggest that, in addition to IDO1, other kynurenine metabolites may regulate the CD4+ T-cells immunity. Moreover, reduction of KMO expression after its exposure to MCLs may serve as an exciting candidate in regulating the kynurenine pathway in tumour immunity (Fig. 5e ) and opens up the possibility that disrupting the metabolism of kynurenines may be used to design novel and more effective treatment strategies. However, more research is still required for a better understanding of the pathogenesis of KP metabolites and their intra-and interconnectivity for a great variety of diseases and disorders.
Methods
Antibodies and reagents. Recombinant IFNγ (cat. 285-IF-100) and 10 µg/mL neutralizing antibodies against IFNγ (cat. AB-285-NA) and anti-mouse IgG1 (clone11711) were purchased from R&D system (McKinley Place NE). INCB024360 (CAS 914471-09-3, 98% pure) was purchased from MedChem Express. L-Tryptophan and KYNA were purchased from Sigma-Aldrich Sweden. For vector transfection, Lipofectamin 3000 was purchased from ThermoFisher Scientific (#L3000008). Wild type BRAF plasmid was a gift from Dustin Maly (Addgene plasmid # 40775; http://n2t.net/addgene:40775; RRID: Addgene_40775). Empty vector pcDNA3.1 and GenElute Plasmid Miniprep Kit (PLN70) were purchased from Invitrogen and Sigma Aldrich, respectively. Primary antibodies, Raf-B (SC-5284) and β-Actin (5125) were purchased from Santa Cruz Technology and Cell Signalling Technology, respectively. Detailed information about the purchased antibodies is provided in Table S1 . CD4+ and cancer cell co-culture assays, transfection, and treatment. Buffy coat samples from healthy donors were acquired from Karolinska University Hospital blood bank, Sweden.
Lymphocytes were isolated from fresh buffy coats by using density gradient centrifugation with Ficoll-Paque Plus (GE Healthcare). CD4+ T-cell subsets were then isolated from PBMC's negative selection, and the CD25+ fraction was additionally depleted with CD25-specific MACS beads following the manufacturer's instructions (Miltenyi Biotec). CD4+ T-cell subsets were pre-activated overnight with LEAF ™ purified anti-human CD3 antibody (2 mg/ml) and CD28 antibody (1 ug/ml). Co-culture models used for investigating the cellular interactions in vitro ( Supplementary Fig. S1b ), MCLs (BE, DFB, A375 and SK-MEL-28), were incubated for 24 hours at a concentration of 1.0 × 10 4 cells/ml with 1 × 10 6 cells⁄ml of activated CD4+ T-cells on the following day and subsequently co-cultured for up to 5 days, with and without aIFNγ and blocking antibody. The two populations were then separated by labeling the CD4+ T-cells against the tumour, using Dynal ® positive isolation kits. The RNA was quantified via TaqMan real-time PCR (Applied Biosystems), and the total amount extracted using an RNeasy Mini kit (Qiagen). Our experimental procedure involved the use of an RNA isolation system, a one-step real-time RT-PCR assay, and a SuperScript VILO cDNA Synthesis Kit (Invitrogen). RPL13A (Ribosomal Protein L13a1) was used as a reference gene. Empty vector pcDNA3.1 and wild-type BRAF expression plasmid were prepared by GenElute Plasmid Miniprep Kit. Immunoblots were performed on whole protein lysates from SK-MEL-28 and DFB cell lines transfected for 72 h with vectors expressing wild type BRAF or empty control vectors following standard protocol from Lipofectamin 3000. The images are not cropped or adjusted in any manner. The exposure time for the figure is three seconds for BRAF and β-actin ( Supplementary Fig. 6a,b ). flow cytometry. Cell surface staining protocol with anti-CD45RA-FTIC, CD4-PerCP/Cy5.5, CD25-PE, CD8A-APC, CD14-PE, and CD19-APC (Table S1 ) was performed to verify the purity of CD4+ T-cells. Viability and proliferation stainings were performed using a fixable viability dye, eFluor 780, and a cell proliferation dye, carboxyfluorescein diacetate succinimidyl ester (CFSE), respectively. Before all intracellular staining, cells were restimulated for 4 hours using ten ng/ml of phorbol 12-myristate 13-acetate (PMA, Sigma) and 375 ng/ml of ionomycin (Iono), in the presence of GolgiPlug protein transport inhibitor containing Brefeldin A (BFA; BD Biosciences). The following human antibodies were used: CD152-APC, CD279-PE, CD274-BV421, FOXP3-APC, IDO1-Alexa flour 700, mouse, IgG2Isotype Control-APC, mouse, IgG2b-PE, mouse IgG1-Alexa flour 700 (Table S1 ). A CyAn ADP 9-Colour Analyser (Beckman Coulter) was used for flow cytometry recording, and CyAn software (Summit) was used for creating the compensation settings using single-stained compensation beads (BD CompBeads, BD Biosciences). Data of flow cytometry were analysed using a FlowJo ® software (Tree Star). cytokine production. Levels of the cytokines IFNγ, tumour necrosis factor alpha (TNFα), IL-10, IL-17, IL-2, and IL-4 in culture medium were determined using a multiplex bead array assay. All the reagents were purchased from R&D Systems. Individual bead sets (Luminex) were coupled to cytokine-specific capture antibodies following the manufacturer's instructions. Data were recorded on the Bio-Plex-200 platform and analysed using the Bioplex Manager ® software (version 6.1; Bio-Rad) with a 5-parameter logistic regression algorithm.
